AlzeCure Pharma (ALZCUR ST) stock market data APIs
kr8.0111
-0.07(-0.9%)
as of September 16, 2026
Try our APIs with
free plan!
AlzeCure Pharma Financial Data Overview
Price chart is built with
Anychart
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinson's disease, which is in phase I clinical trial; ACD857 and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist, which is in phase II clinical trial for neuropathic pain indications; and ACD137 negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications, which is in preclinical phase. AlzeCure Pharma AB (publ) was founded in 2012 and is based in Huddinge, Sweden.
Prev. Close
8.0111
Open
7.9384
High
8.1052
Low
7.9217
52 wk Range
1.1642-8.68
Market Cap
919 M
P/E Ratio
24.2424
Shares Outstanding
115 M
Revenue
97 326 K
EPS
0.5815
Beta
-0.074
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get AlzeCure Pharma data using free add-ons & libraries
Get AlzeCure Pharma Fundamental Data
AlzeCure Pharma Fundamental data includes:
- Net Revenue: 97 326 K
- EBITDA: 31 466 K
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-26
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AlzeCure Pharma News
New
AlzeCure Pharma to Present at Aktiedagen in Stockholm on September 15
STOCKHOLM, SE / ACCESS Newswire / September 8, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6) , which develops small-molecule drug candidates for CNS diseases with a foc...
AlzeCure Receives a USD 10 Million Upfront Payment and Completes Initial Transaction with Lilly
STOCKHOLM, SE / ACCESS Newswire / August 18, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company")(STO:ALZCUR)(FRA:AC6) , which develops small-molecule drug candidates for CNS diseases with a focus ...
Lilly Makes a New Alzheimer's Pipeline Move
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) is adding another Alzheimer's bet, striking a collaboration and licensing deal with Swedish biotech AlzeCure Pharma that could be worth ...
Eli Lilly Signs Alzheimer's Licensing Deal Worth Over $1 Billion With AlzeCure
Eli Lilly (LLY) shares were up early Tuesday as the drugmaker entered into a collaboration and licen PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Get AlzeCure Pharma fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
